{"id":"https://openalex.org/W2014332245","doi":"https://doi.org/10.1001/jamaoncol.2015.0702","title":"Cabozantinib\u2014Getting Under the Skin of Cutaneous Toxicity","display_name":"Cabozantinib\u2014Getting Under the Skin of Cutaneous Toxicity","publication_year":2015,"publication_date":"2015-04-30","ids":{"openalex":"https://openalex.org/W2014332245","doi":"https://doi.org/10.1001/jamaoncol.2015.0702","mag":"2014332245","pmid":"https://pubmed.ncbi.nlm.nih.gov/26181263"},"language":"en","primary_location":{"id":"doi:10.1001/jamaoncol.2015.0702","doi":"https://doi.org/10.1001/jamaoncol.2015.0702","is_oa":false,"landing_page_url":"https://doi.org/10.1001/jamaoncol.2015.0702","pdf_url":null,"source":{"id":"https://openalex.org/S2756165422","display_name":"JAMA Oncology","issn_l":"2374-2437","issn":["2374-2437","2374-2445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008796630","display_name":"Anuradha Jayaram","orcid":"https://orcid.org/0000-0002-5255-8909","observed_orcids":["https://orcid.org/0000-0002-5255-8909"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Anuradha Jayaram","raw_affiliation_strings":["The Institute of Cancer Research, Royal Marsden Hospital, London, England"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Institute of Cancer Research, Royal Marsden Hospital, London, England","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080919044","display_name":"Zafeiris Zafeiriou","orcid":"https://orcid.org/0000-0001-8059-2736","observed_orcids":["https://orcid.org/0000-0001-8059-2736"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Zafeiris Zafeiriou","raw_affiliation_strings":["The Institute of Cancer Research, Royal Marsden Hospital, London, England"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Institute of Cancer Research, Royal Marsden Hospital, London, England","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I4210121186"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Johann S. de Bono","raw_affiliation_strings":["The Institute of Cancer Research, Royal Marsden Hospital, London, England"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Institute of Cancer Research, Royal Marsden Hospital, London, England","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I4210121186"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5072378199"],"corresponding_institution_ids":["https://openalex.org/I142947616","https://openalex.org/I4210121186"],"apc_list":null,"apc_paid":null,"fwci":1.8613,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":{"value":0.84746256,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"1","issue":"4","first_page":"535","last_page":"535"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12433","display_name":"Skin Diseases and Diabetes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cabozantinib","display_name":"cabozantinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cutaneous-adverse-effects","display_name":"cutaneous adverse events","score":0.890999972820282},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9079999923706055},{"id":"https://openalex.org/keywords/hand-foot-skin-reaction","display_name":"hand-foot skin reaction","score":0.8619999885559082},{"id":"https://openalex.org/keywords/skin-toxicity","display_name":"skin toxicity","score":0.625},{"id":"https://openalex.org/keywords/multikinase-inhibitor","display_name":"multikinase inhibitor","score":0.7620000243186951},{"id":"https://openalex.org/keywords/metastatic-urothelial-carcinoma","display_name":"metastatic urothelial carcinoma","score":0.9399999976158142},{"id":"https://openalex.org/keywords/vegfr","display_name":"VEGFR","score":0.5870000123977661},{"id":"https://openalex.org/keywords/c-met","display_name":"c-Met","score":0.9390000104904175},{"id":"https://openalex.org/keywords/alopecia","display_name":"hair loss","score":0.7509999871253967},{"id":"https://openalex.org/keywords/pruritus","display_name":"pruritus","score":0.7789999842643738}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9446054697036743},{"id":"https://openalex.org/C2781064419","wikidata":"https://www.wikidata.org/wiki/Q795057","display_name":"Cabozantinib","level":3,"score":0.8592827320098877},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.7013945579528809},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.5269409418106079},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.36140087246894836},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3255852460861206},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.26009994745254517},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1278703510761261}],"mesh":[{"descriptor_ui":"D000813","descriptor_name":"Anilides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D001749","descriptor_name":"Urinary Bladder Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003875","descriptor_name":"Drug Eruptions","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D012867","descriptor_name":"Skin","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1001/jamaoncol.2015.0702","doi":"https://doi.org/10.1001/jamaoncol.2015.0702","is_oa":false,"landing_page_url":"https://doi.org/10.1001/jamaoncol.2015.0702","pdf_url":null,"source":{"id":"https://openalex.org/S2756165422","display_name":"JAMA Oncology","issn_l":"2374-2437","issn":["2374-2437","2374-2445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA Oncology","raw_type":"journal-article"},{"id":"pmid:26181263","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26181263","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA oncology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9789000153541565,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.7599999904632568,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W1972446507","https://openalex.org/W2012072673","https://openalex.org/W2100512801","https://openalex.org/W2155806795","https://openalex.org/W2442934755"],"related_works":["https://openalex.org/W2073965827","https://openalex.org/W3114001070","https://openalex.org/W4206525868","https://openalex.org/W2049455380","https://openalex.org/W4399660922","https://openalex.org/W2112099875","https://openalex.org/W4415716704","https://openalex.org/W1981413407","https://openalex.org/W2117927681","https://openalex.org/W7114785342"],"abstract_inverted_index":{"Tyrosine":[0],"kinases":[1],"(TKs)":[2],"are":[3,29,60],"a":[4,10,64,112,139,208,235],"family":[5],"of":[6,40,52,66,136,142,166,180,199,210,218,228],"proteins":[7],"that":[8,107],"play":[9],"key":[11],"role":[12,51],"in":[13,44,55,201,214],"themost":[14],"fundamental":[15],"cellular":[16],"processes":[17],"including":[18],"the":[19,37,50,176,197,250,256],"cell":[20,24],"cycle,":[21],"proliferation,":[22],"differentiation,":[23],"death":[25],"and":[26,28,96,188,221,226,246],"survival":[27],"crucial":[30],"inoncogenesis.":[31],"Tyrosinekinase":[32,102],"inhibitors":[33,103],"(TKIs)":[34],"actby":[35],"inhibiting":[36],"catalytic":[38],"subunit":[39],"TKs.":[41],"Clinical":[42],"trials":[43,153],"several":[45],"cancer":[46,56],"types":[47],"have":[48],"established":[49],"these":[53,143],"drugs":[54],"therapeutics.":[57],"Although":[58],"TKIs":[59,137,155],"\u201ctargeted":[61],"therapeutics,\u201dmany":[62],"inhibit":[63],"range":[65],"kinase":[67],"receptorswithvariedpotencyand":[68],"selectivity.":[69],"Targeted":[70],"receptors":[71,80],"include":[72,118],"vascular":[73],"endothelial":[74],"growth":[75,87,98],"factor":[76,83,88,99],"receptor":[77,84,89,100],"(VEGFR),":[78],"platelet-derivedgrowthfactor":[79],"(PDGFRs),":[81],"fibroblastgrowth":[82],"(FGFR),":[85],"epidermal":[86],"(EGFR),":[90],"c-KIT,":[91,244],"FLT-3,":[92],"c-MET,":[93,242],"MEK,":[94],"BRAF,":[95],"insulin-like":[97],"(IGFR).1":[101],"causeaspectrumofdermatologic":[104],"adverse":[105,116,145],"events":[106,146],"has":[108],"been":[109],"described":[110],"as":[111],"\u201cclass":[113],"effect.\u201d":[114],"These":[115],"effects":[117],"rash,":[119],"hand-foot-skin":[120],"reaction":[121],"(HFSR),":[122],"alopecia,":[123],"depigmentation,":[124],"pruritus,":[125],"xerosis,":[126],"acneiform":[127],"rashes,":[128],"scrotal":[129],"lesions,":[130],"andmucositis.":[131],"The":[132],"distinctmultikinase":[133],"inhibition":[134],"profile":[135],"produces":[138],"different":[140],"constellation":[141],"cutaneous":[144],"(CEs).2":[147],"Despite":[148],"this":[149],"spectrum,many":[150],"phase":[151],"3":[152],"involving":[154],"reportedCEscollectivelyas":[156],"\u201cskin":[157],"toxicity.\u201dThere":[158],"isclearlyaneed":[159],"forgreaterdetail":[160],"anddescriptionsof":[161],"therangeofCEsrelatedtothese":[162],"agents.":[163],"In":[164,248],"support":[165],"this,":[167],"one":[168],"meta-analysis2":[169],"focusing":[170],"on":[171],"CEs":[172,200],"reportedonlyonHFSR,":[173],"andpruritus.":[174],"Toelucidate":[175],"full":[177],"potential":[178],"diversity":[179],"CEs,":[181],"2":[182],"small":[183],"prospective":[184],"trials3,4":[185],"with":[186,204],"sorafenib":[187],"sunitinib,":[189],"respectively,":[190],"were":[191,231],"designed.":[192],"Zuo":[193],"et":[194],"al":[195],"report":[196],"incidence":[198],"patients":[202],"treated":[203],"cabozantinib":[205],"administered":[206],"at":[207],"dose":[209],"60":[211],"mg/d":[212],"continuously":[213],"metastatic":[215],"urothelial":[216],"carcinomabymeans":[217],"dedicated":[219],"history":[220],"physical":[222],"examination.Adermatologist":[223],"reviewedpatientsonlywhen":[224],"signs":[225],"symptoms":[227],"skin":[229],"toxicity":[230],"present.":[232],"Cabozantinib":[233],"is":[234],"potent,":[236],"small-molecule,":[237],"oral":[238],"multi-TKI":[239],"targeting":[240],"VEGFR2,":[241],"RET,":[243],"AXL,":[245],"FLT3.":[247],"2012,":[249],"US":[251],"Food":[252],"andDrug":[253],"Administrationapprovedcabozantinib":[254],"for":[255],"treatmentofmetastaticmedJAMADERMATOLOGY":[257]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}